http://www.northcoastbio.com/NCB/Applications.html?fbclid=IwAR3YiFthAtFWMBZoFVxwnkdBkvBQgSzRGk-4ApyaJkqh4zT_Qdtz2vlBcps
Our Purpose:
The Technology: BLAST
Mab in-license opportunities:
“Applications of BLAST
“BLAST is a method that physically displays an entire, native IgG immune response in an easily assayable format for discovering antibodies with desired function or features. For the first time, immune responses from various mammals (humans included) can be sampled thoroughly and efficiently for rare antibodies of high affinity or function for therapeutic antibody discovery. BLAST has been configured for speed (7 days to see results from B-cells to screens) and flexibility in that it has been industrialized to the degree that you can “work at the speed of thought”. An entire immunological history of acute or chronic disease can be assayed or monitored for both efficacious antibodies and their associated targets or epitopes. All antibodies are delivered humanized when non-human species are used.
“North Coast Bio is an antibody company committed to the discovery and generation of antibody therapeutics for serving unmet medical needs and/or to replace antibodies to known, validated targets that under perform either via partnerships or our own internal efforts.
“The company was founded for the sole purpose of free and creative deployment of the main technology into the typical areas, but also to include those that traditional venture backed companies cannot serve. Our goal is to choose disease indications based on unmet need rather than market size alone while simultaneously partnering BLAST with biotech companies or pharma’s who wish to co-discover and subsequently develop antibodies that suit their clinical interests.
“The BLAST platform has been engineered for flexibility and for speed.
“BLAST in humans can sample the native immune repertoire for:
-
•anti-infective antibodies against viruses or bacteria from individuals infected (titer+) or vaccinated
-
•tumor-specific antibodies from “normal” individuals as well as those currently with cancer
-
•therapeutic antibodies from auto-immune patients where those antibodies that are part of the pathology of their disease are actually efficacious in another
-
•antibodies that reveal epitopes that are either responsible for an auto-immune disease (for targeting) or reveal neutralizing epitopes that can be used to engineer new vaccines.
“BLAST in other immune animals such as rabbits, mice, or macaque creates the opportunity to find antibodies with exceptional therapeutic qualities by producing a treasure trove of selectable antibodies due to access to millions of IgG’s afforded by the BLAST approach.
Personalized Medicine: Compassionate Use of BLAST
Partnering:
“North Coast Bio is funded solely via partnerships with pharma, biotech companies, and academic institutions. We are soliciting partnerships to take advantage of BLAST for discovery of novel therapeutic antibodies/targets or generation of therapeutic antibodies to known targets that out perform the respective current sub-par approved antibodies. Our areas of focus are cancer, infectious disease, auto-immunity, and vaccine monitoring (reverse vaccinology). BLAST is readily used to either discover new epitopes for vaccine development, or to monitor vaccine responses down to the epitope which provide the greatest therapeutic effect either pre-clinically or in clinical trials.
“It’s time for our local biotech community to get off our collective asses and make things happen. Do you have an idea for a therapeutic antibody but are forbidden to pursue it? Conforming to the current conservative way is killing our industry. There are so many therapeutics waiting to be discovered and generated using antibodies. We’ve given our local physicians virtually nothing to work with since the mid 90’s with Rituxan, Herceptin, and Erbitux. While these are great drugs, we don’t need more of the same. If you have a great idea, take some risk, get your work plan together and come to North Coast and execute the plan. We’ve let far too many cancer patients die from tumors that are very treatable with antibodies. If the established companies won’t pursue discovery of new targets in these areas,…..we will. Bring it…..
Economic stimulus with antibodies:
